nemolizumab   Click here for help

GtoPdb Ligand ID: 8720

Synonyms: CD14152 | CIM 331 | CIM331 | Mitchga® | Nemluvio®
Approved drug Immunopharmacology Ligand
nemolizumab is an approved drug (Japan (2022), FDA (2024))
Compound class: Antibody
Comment: Nemolizumab is an investigational monoclonal targeting the α subunit of the IL-31 receptor. Nemolizumab has been designed for treating or preventing inflammatory diseases [3].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis of patented peptide sequences reveals that the heavy and light variable domains of nemolizumab are identical to SEQ ID NO: 210 and SEQ ID NO: 220 respectively, in patent US8575317 B2 [4]. This combination of peptides corresponds to one of the preferred antibodies, designated as H44L17 therein.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
A Phase 1 safety, tolerability and PK study detected no serious adverse events in any of the trial subjects, and nemolizumab reduced pruritus and use of hydrocortisone in patients with atopic dermatitis (AD) [5]. Nemolizumab was advanced to Phase 2 & 3 clinical evaluations [1-2]. First approval was granted in Japan (March 2022) for the treament of unresolved itch associated with AD. The FDA authorised nemolizumab to treat prurigo nodularis in August 2024.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03989206 Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Phase 3 Interventional Galderma R&D
NCT04204616 A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Phase 3 Interventional Galderma R&D